Celldex Therapeutics Strong Cash Runway Supports Barzolvolimabs Path To Market
…
23,578$
-8,40%
Echtzeit-Aktienkurs Celldex Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Celldex Therapeutics Inc. Aktie
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the…
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient…
Celldex Therapeutics: Rising High, With Room For Further Growth
…
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci,…
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced…
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced…
Why Celldex Therapeutics Blasted 13% Higher on Monday
The biotechs CSU treatment advanced in the laboratory.…
Biggest stock movers today: Paramount Global, Organigram, Celldex Therapeutics and more
…
: Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
…
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing…
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Celldex Therapeutics, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient…
Form 8-K Celldex Therapeutics, For: Jun 15
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment…
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
HAMPTON, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient…
Celldex GAAP EPS of -$0.62, revenue of $1M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?
Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
Form 8-K Celldex Therapeutics, For: Mar 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex GAAP EPS of -$0.56 beats by $0.03, revenue of $1.61M beats by $1.35M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Celldex Therapeutics, For: Feb 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by…
Celldex Therapeutics Shares Gain 13% On Positive Barzolvolimab Study Data
Celldex Therapeutics Shares Gain 13% On Positive Barzolvolimab Study Data...…
Celldex gains 12% on Phase 1 data for urticaria candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class…
Form 8-K Celldex Therapeutics, For: Feb 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort -...…
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate…
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the…
Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline
Celldex (CLDX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…